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Abstract: Reference methods for antifungal susceptibility testing of yeasts have been developed by
the Clinical and Laboratory Standards Institute (CLSI) and the European Committee on Antibiotic
Susceptibility Testing (EUCAST). These methods are intended to test the main pathogenic yeasts that
cause invasive infections, namely Candida spp. and Cryptococcus neoformans, while testing other yeast
species introduces several additional problems in standardization not addressed by these reference
procedures. As a consequence, a number of procedures have been employed in the literature to
test the antifungal susceptibility of Malassezia pachydermatis. This has resulted in conflicting results.
The aim of the present study is to review the procedures and the technical parameters (growth media,
inoculum preparation, temperature and length of incubation, method of reading) employed for
susceptibility testing of M. pachydermatis, and when possible, to propose recommendations for or
against their use. Such information may be useful for the future development of a reference assay.
Keywords: Malassezia pachydermatis; susceptibility testing; broth microdilution; disk diffusion;
minimum inhibitory concentration (MIC)
1. Introduction
The genus Malassezia is now known to include different species of yeast, many of which have
been associated with various diseases in humans and animals [1,2]. Malassezia pachydermatis is the lone
lipophilic, but not lipid-dependent, species of this genus. The other species show an absolute
requirement for long fatty acid chains and specific procedures are required for their isolation [3].
M. pachydermatis colonizes the skin and mucosal sites of healthy dogs and cats. Favorable growth
conditions in the local environment allow excessive multiplication of this organism, which may then
function as an opportunistic secondary pathogen. Malassezia dermatitis and otitis, inflammatory
diseases associated with elevated populations of M. pachydermatis on the skin and in the ear
canal of dogs and cats, have been recognized with increasing frequency [4,5]. The underlying
conditions leading to the yeast overgrowth include hypersensitivity diseases (atopy, adverse cutaneous
food reactions, flea bite hypersensitivity, and contact allergy), cornification disorders, ectoparasite
infection, bacterial pyoderma, and endocrine diseases (hyperadrenocorticism, hypothyroidism,
diabetes mellitus). Moreover, a hypersensitivity response to the yeast itself is likely to occur
in many allergic dogs [4–6]. Current treatment options for Malassezia dermatitis/otitis in dogs
include systemic and/or topical therapy with a number of antifungal agents, in addition to
various antiseptics. Azole derivatives (itraconazole—ITZ; ketoconazole—KTZ; miconazole—MCZ;
J. Fungi 2017, 3, 37; doi:10.3390/jof3030037 www.mdpi.com/journal/jof
J. Fungi 2017, 3, 37 2 of 15
clotrimazole—CTZ etc.) are the more common choice, though other agents belonging to various
chemical classes are also used (terbinafine—TER; thiabendazole—TBZ) [4,5,7–9]. Although the dog
is the main host, M. pachydermatis may be found to cause bloodstream infections in humans. Infections
have been linked to the administration of lipids through intravenous catheters, especially in infants
in intensive care units. M. pachydermatis is considered to be transferred from a household pet as it
is rarely isolated from normal human skin, but may be transferred on the hands of healthcare workers
or family members [2,10–14]. Fungemia by M. pachydermatis in human patients is treated with azoles
(e.g., fluconazole—FCZ) and other agents (e.g., amphotericin B—AMB) [2,11].
Based on the results of in vitro susceptibility tests, some studies have claimed resistance towards
various agents for variable proportions of strains of M. pachydermatis isolated from dogs (e.g., 8% [15,16]
and 20% [17] towards ITZ; 14% towards TBZ [18]; 24% towards KTZ [19]; 4% towards CTZ, MCZ,
and nystatin (NYS) [20]). However, this issue remains controversial for now, principally due to
the lack of a specific reference procedure for antifungal susceptibility testing (AFST). Therefore, a strain
considered resistant using a certain method may appear susceptible (and vice-versa) under different
test conditions.
This review aims to describe and discuss past experiences concerned with AFST of M. pachydermatis,
with the intention of identifying the technical parameters that might be more suitable in order to increase
the end-point evaluation and reproducibility of susceptibility tests for this organism. Such information
may represent a good starting point for the future development of a reference assay.
2. Current Status of Antifungal Susceptibility Testing Methods
Until recently, the techniques for antifungal susceptibility testing were not standardized,
consequently inter- and even intra-laboratory reproducibility was poor. Different testing variables,
including test format, inoculum size, test medium composition, temperature, duration of incubation,
and endpoint determination, are known to have an impact on in vitro determinations [21–24].
With regard to yeasts, the first properly optimized and standardized method was a broth macrodilution
method developed by the Clinical and Laboratory Standards Institute (CLSI) (formerly the National
Committee for Clinical Laboratory Standards). This proved unwieldy for testing large numbers
of isolates, and it was later adapted to allow for a microdilution format in microtitre plates,
and the updated version of this method, reported in CLSI documents M27-A3 [25] and M27-S4 [26],
is now a widely accepted standard [21–24,27]. The method, intended for testing Candida spp. and
Cryptococcus neoformans, relies on measurements of growth inhibition during exposure over a defined
time period to a range of doubling drug concentrations diluted in liquid medium, with results
expressed as the minimum concentration of the drug able to inhibit fungal growth (minimum inhibitory
concentration (MIC)). A standard antifungal disk diffusion susceptibility testing method for Candida
vs. some antifungal agents is now also available [27–29]. The European Committee on Antibiotic
Susceptibility Testing (EUCAST) has also published guidelines for testing Candida isolates [30,31].
The EUCAST method is principally similar to the CLSI M27-A3 assay with modifications concerning
some of the test parameters [28] (Table 1).
Thanks to the development of these reference methods for AFST, it is now possible to produce
in vitro susceptibility results that are comparable between laboratories and allow epidemiological
analyses at the national and even international level. In addition, the utility of antifungal susceptibility
tests as an adjunct in optimizing the treatment of candidiasis has now been validated, at least for
some clinical presentations/drug combinations [28]. However, in terms of predicting the outcome of
therapy, several factors (e.g., pharmacokinetics of drugs, the immune system of the host, virulence
factors of the infecting microorganism, etc.) have been shown to outweigh the importance of
antifungal susceptibility testing [24,27,32]. Accordingly, the interpretative breakpoints now available
for Candida spp. have been based on a number of pharmacodynamic and pharmacokinetic
analyses (e.g., the evaluation of the duration of the dosing interval where the drug concentration
in the tissue remains above the MIC for the infecting pathogen and the ratio of the area under
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the time–concentration curve to the MIC), but the proof of their validity has ultimately come from
analysis of the in vitro–in vivo correlation in clinical practice [24]. In this regard, the so-called
“90-60 rule”, which maintains that infections due to susceptible (S) strains of Candida spp. respond to
appropriate therapy in ~90% of cases, whereas infections due to resistant (R) strains respond in ~60%
of cases, well illustrates that in vitro susceptibility does not always predict a successful therapy while
in vitro resistance often, but not always, predicts therapeutic failure [22,27].
Table 1. Main parameters for the performance of the Clinical and Laboratory Standards Institute
(CLSI) broth methods (M27-A3 and M27-S4 documents) (with European Committee on Antibiotic
Susceptibility Testing (EUCAST) modifications) and disk diffusion method (M44-A and M44-S2
documents) for yeasts. Data from Arikan (2007) [28] and Canton et al. (2009) [27].
Parameter Broth-Method Disk-Diffusion Method
Test medium
Roswell Park Memorial Institute Medium
(RPMI-1640) with glutamine, without
bicarbonate. Glucose concentration: 0.2%
(EUCAST 2%)
Mueller-Hinton agar + 2% glucose
+ 0.5 mg/L methylene blue
Inoculum size 0.5 × 10
3–2.5 × 103 CFU/mL
(EUCAST 1 × 105–5 × 105)
0.5 Mc Farland standard
(1 × 106 to 5 × 106 CFU/mL)
Microdilution plates 96 U-shaped wells (EUCAST flat-bottom wells) NA
Temperature and
incubation time
Candida spp., 48 h a at 35 ◦C (EUCAST 24 h)
Cryptococcus neoformans, 72 h at 35 ◦C
35 ◦C for 20–24 h
Some strains of Candida glabrata,
Candida krusei, and Candida parapsilosis
often require 48 h
Reading method Visual (EUCAST Spectrophotometric 530 nm) Measurement of zone size
a = Reading at 24 h is acceptable, provided that fungal growth is adequate, for amphotericin B, and fluconazole.
Echinocandins must be read at 24 h; NA = not applicable.
Modifications of the available methods as well as other methodologies that might have particular
advantages, such as ease of performance, economy, or more rapid results are also being intensively
studied [28]. For example, the agar dilution method is a conventional method that has been studied
for various antifungal agent/yeast species combinations. Although still unstandardized, it has been
shown to produce good correlation with microdilution methods in most of the comparative studies [28].
An agar dilution method may be of interest for some difficult-to-grow fungi and it is indeed under
investigation for lipid-dependent Malassezia species [28]. Another example is the E-test®, and more
recently the introduction of other commercial gradient strips, in which a plastic test strip is impregnated
with a continuous concentration gradient of an antifungal agent. This way, an MIC can be obtained
in an agar diffusion test, by considering where the border of the inhibition zone intercepts the graded
MIC scale on the E-test strip. The agreement of E-test with the CLSI reference method is variable,
but frequently above acceptable limits [27,28].
3. Antifungal Susceptibility Testing of Malassezia pachydermatis
Compared with the extensive work done for Candida and Cryptococcus, the value of in vitro
susceptibility testing has been much less comprehensively investigated for M. pachydermatis. As a result,
standard parameters and guidelines specifically dedicated to this yeast are not available yet and
neither are the interpretive criteria. Moreover, the conditions employed in the CLSI/EUCAST methods
are almost universally accepted to not be suitable for M. pachydermatis, particularly due to the lipid-free
medium (RPMI broth), which does not support adequate growth of the yeast [33,34]. Other problems
are the slower growth rate compared to that of Candida species and the tendency to form clusters [34].
Therefore, different adjustments have been adopted in the literature [15–20,33–65]. Unsurprisingly,
this has resulted in conflicting results. For example, Table 2 reports MICs obtained for some antifungals
belonging to different chemical classes and with different mechanisms of action.
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Table 2. Some minimum inhibitory concentrations (MICs, µg/mL) of different antifungal agents
against isolates of M. pachydermatis reported in the literature.
Drug Ref. Format N◦ Range MIC50 MIC90 CBS 1879
AMB
Prado et al. (2008) [57] BMD 50 ND ND 2 a Not tested
Brito et al. (2009) [37] BMD 20 0.25 b 0.25 0.25 Not tested
Velegraki et al. (2004) [62] BMD 1 0.12
b NA NA Not tested
E-test 1 0.5 b NA NA Not tested
Brito et al. (2007) [38] AD 32 0.125–8 0.5 8 Not tested
MCZ
Uchida et al. (1990) [61] BMD 42 0.16–>80 1.25 20 2.5
Gordon et al. (1988) [44] BMD 7 0.009–0.039 ND ND Not tested
Pietschmann et al. (2008) [56] BMD 1 2.92 NA NA 2.92
Hensel et al. (2009) [46] BMD 24 0.03–0.5 0.125 0.25 Not tested
Peano et al. (2012) [34] BMD 51 0.03–16 2 4 Not tested
ITZ
Murai et al. (2002) [50] BMD 24 1.6 b 1.6 1.6 1.6
Garau et al. (2003) [43] BMD 10 ≤0.03–0.06 ≤0.03 0.06 Not tested
Eichenberg et al. (2003) [42] BMD 82 0.007–0.125 0.06 0.125 Not tested
Rincon et al. (2006) [58] BMD 3 0.03–0.125 NA NA 0.06
Prado et al. (2008) [57] BMD 50 ND ND <0.03 a Not tested
Brito et al. (2009) [37] BMD 20 ≤0.03–0.25 ≤0.03 ≤0.03 Not tested
Jesus et al. (2011) [17] BMD 30 0.01–1 0.125 0.5 Not tested
Nascente et al. (2003) [19]
BMD 24 0.03–4 0.125 0.5 Not tested
E-test 35 0.002–2 0.003 0.016 Not tested
Velegraki et al. (2004) [62] BMD 1 0.06
b NA NA Not tested
E-test 1 0.12 b NA NA Not tested
Nijma et al. (2011) [54] BMD 30 <0.03–2 <0.03 <0.03 <0.03
E-test 30 <0.03–8 <0.03 <0.03 <0.03
Nakamura et al. (2000) [51]
BMD 12 0.8–6.3 ND ND Not tested
AD 12 0.4–6.3 ND ND Not tested
Gupta et al. (2000) [45] AD 4 ≤0.03 b NA NA ≤0.03
Sugita et al. (2005) [60] AD 6 0.016 b NA NA Not tested
Brito et al. (2007) [38] AD 32 ≤0.0075 b ≤0.0075 ≤0.0075 Not tested
TER
Murai et al. (2002) [50] BMD 24 3.2 b 3.2 3.2 3.2
Weseler et al. (2002) [65] BMD 9 0.2–1.6 NA NA Not tested
Velegraki et al. (2004) [62] BMD 1 0.12 NA NA Not tested
E-test 1 NA c - - Not tested
Gupta et al. (2000) [45] AD 4 ≤0.03 b NA NA ≤0.03
AMB = Amphotericin B; MCZ = miconazole; ITZ = itraconazole; TER = terbinafine; BMD = microdilution broth
format; AD = agar dilution; N◦ = number of isolates tested; ND = not defined; NA = not applicable since <10 strains
tested; a = the MIC was defined as the lowest antifungal concentration with the lowest number of strains with colony
counting similar to the drug-free control for azole drugs, or the lowest concentration that completely inhibited
fungal growth for AMB; b = no range, only one strain tested or MICs equal for all of the strains; c = E-Test strip
was not available for TER. The last column documents the MICs obtained for the reference strain of M. pachydermatis
CBS 1879 (collection of the Westerdijk Fungal Biodiversity Institute, formerly the Fungal Biodiversity Center—CBS,
Utrecht, The Netherlands).
This “method dependency” of MICs is clearly shown by the highly variable results obtained by
different authors for a reference strain of the yeast (M. pachydermatis CBS 1879) (Table 2). This conflicting
situation applies also to studies that employed procedures based on agar diffusion from disks.
For example, thiabendazole (TBZ) was completely ineffective in a disk diffusion test [48] whilst a recent
study reported MIC values of the agent for all strains tested [34].
3.1. The Test Conditions
Various test formats have been employed at different times. The most popular approach
was the broth microdilution methodology (BMD), followed by agar dilution (AD), disk diffusion
(ADiff), Etest, and broth macrodilution (BMaD) techniques. Some authors compared two different test
formats. A detailed description of the technical parameters adopted thus far is provided in the online
version of this article (Table S1).
J. Fungi 2017, 3, 37 5 of 15
3.1.1. The Growth Medium in Broth-Based Techniques
Most of the growth media were formulations with lipid components included to enhance
the yeast growth. Often these lipid sources (tween, glycerol, olive oil, oleic acid, ox bile, or cow’s
milk fat), were added to a medium “base”, for example Christensen’s Urea, Sabouraud’s, and RPMI
medium [15,34,40,56–58], while occasionally some authors employed media specifically developed for
culturing lipid-dependent Malassezia species, such as Leeming-Notman and Dixon’s medium [43,54],
that are very complex and contain a large quantity of lipid components. Regardless of the complexity
of the medium, almost all authors who used broth-dilution procedures appear to agree that
a certain lipid supplementation is mandatory when testing M. pachydermatis in a liquid medium.
This supplementation was instead unnecessary in many studies in which solid media were employed.
This agrees with the fact that although M. pachydermatis is distinguished within the Malassezia genus for
its capacity to grow in vitro without supplementation with fatty acids, it generally exhibits this feature
if cultured on solid media (e.g., Sabouraud Dextrose agar, SDA) [66], while in a lipid-free broth it often
fails to grow or grows poorly. In such a nutritionally suboptimal situation the antifungal activity may
thus be exaggerated. Such an effect, especially a partial growth, could be highly misleading when
interpreting the susceptibility test results. In this situation the yeast might also grow to a certain extent
in the control drug-free wells/tubes and this could suggest to an operator that a test was carried out
correctly, while the activity of the drug under examination was probably overestimated (Figure 1).
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rows of wells contain doubling dilutions of the drugs from 4 to 0.007 µg/mL with the highest 
concentration to the left of the plate. For this experiment, the MICs were 0.06 (ITZ) and 4 (MCZ) 
µg/mL if tested in the lipid-supplemented broth; or 0.007 µg/mL for both drugs if tested in the lipid-
free broth. In this latter medium, a yeast growth is visible only in the control wells. A partial color 
change due to the urease activity of the yeast and consequent rise of pH, is visible in some wells. It 
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Figure 1. Microtitre plate (flat-bottom wells) illustrating susceptibility testing of a M. pachydermatis
isolate against two antifungal drugs (ITZ: rows 1–2 and 5–6 and MCZ: rows 3–4 and 7–8) tested
in duplicate with two different media (Urea Christensen Broth with Tween 40 and 80 as lipid source,
rows 1–4; lipid-free Sabouraud broth, rows 5–8). The last column on the right comprises the drug-free
growth controls. The last c lumn on the left is the negative control (no yeast inoculum; no drug).
The rows of wells contain doubling dilutions of the drugs from 4 to 0.007 µg/mL with the highest
concentration to the left of the plate. For this experiment, the MICs were 0.06 (ITZ) an 4 (MCZ) µg/mL
if tested in the lipid-supplemented broth; or 0.007 µg/mL for both drugs if tested in the lipid-free broth.
In this latter medium, a yeast growth is visible only in the control wells. A partial color change due to
the urease activity of the yeast and consequent rise of pH, is visible in some wells. It can be also noted
that the yeast produced a diffuse turbidity in the wells.
Another fundamental feature expected from a medium employed for susceptibility tests is the lack
of interference towards the drugs under testing. In this regard, several examples exist of obfuscation
of the in vitro activity of various antifungals by some complex, undefined (and undefinable)
formulations [67–69]. Analysis of past results seems to indicate that the growth media employed to
test M. pachydermatis, including even the most complex ones, may not actually have a great impact
on the in vitro activity of the antifungal drugs under testing. If there had been obfuscation of activity
then we would have expected reports of very high MICs (or even no inhibition at all) for isolates
tested in a given medium. Nonetheless, it seems logical that a medium selected for susceptibility
testing (of M. pachydermatis, or of any organism) should first undergo a verification of the “absence of
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antagonism”, whereas only a few media employed for M. pachydermatis testing have been assessed
in this way. In particular, Christensen’s broth with Tween 40/80, Sabouraud Broth with Tween 80 and
RPMI with glycerol, and Tween 20 and ox bile were proven to not antagonize the drugs under testing on
the basis that the MIC results for quality control strains belonging to other yeast species—Candida krusei
ATCC 6258, C. neoformans ATCC 90112, and Candida parapsilosis ATCC 22019—were within the expected
ranges obtained in RPMI by the CLSI reference method [33,57,58]. However, it is important to note
that one of these media (lipid-supplemented RPMI) was shown to not produce a satisfactory yeast
growth in one study [33].
The detection and characterization of antagonism should be facilitated with a chemically defined
fully synthetic medium. Accordingly, CLSI/EUCAST elected to test Candida and Cryptococcus
in RPMI broth, that is a fully synthetic medium, thus with a definable and reproducible formula,
and is inert towards antifungal activity [28]. Unfortunately, such a medium is traditionally considered
unsuitable for Malassezia (including M. pachydermatis) testing, owing to its lack of lipid supplementation.
Thus, the recent reports of Jesus et al. (2011) [17] and Weiler et al. (2013) [64], who claimed to have tested
M. pachydermatis in RPMI broth, are surprising. The explanation proposed in one of the studies [17],
that the subcultures that were performed on a lipid enriched medium (Dixon agar) prior to testing
avoided the depletion of lipid reserves of the yeast and allowed the subsequent growth in RPMI,
is intriguing but requires further confirmation. Moreover, the authors [17] supported their findings by
the observation that M. pachydermatis can be separated from the other Malassezia species by its ability
to grow on lipid-free media. This is undoubtedly true, but such ability is generally only displayed
on solid media, while in liquid medium some growth may occur but is unlikely to be adequately
vigorous to provide suitable conditions for testing the activity of an antifungal drug. Regardless of
the potential impact of the lipid supplementation on the drug’s activity, it is necessary to consider that
this enrichment may have another negative implication. Lipid-enriched media are frequently turbid,
which would make it difficult to assess the turbidity due to the yeast growth and therefore accurately
assess the endpoint (see Section 3.1.6).
3.1.2. The Growth Medium in Agar Dilution Assays
With regard to the agar dilution methodology, Gupta et al. (2000) [45] reported that Leeming–Notman
agar (LNA), as a very complex, undefined medium specifically developed for culturing lipid-dependent
Malassezia species, did not interfere with drug activity. This conclusion was drawn from the observation of
similar MIC values for certain Malassezia species (M. restricta, M. obtusa and M. globosa) obtained in LNA
and the defined Diagnostic Sensitivity Testing (DST; Oxoid, UK.) agar. The lack of drug antagonism by
LNA was then confirmed, as noted by the authors themselves, by the low MICs of the antifungal drugs
tested against most of the isolates.
3.1.3. The Growth Medium in Agar Diffusion Assays
Concerning the method of agar diffusion by disks, various media were employed, i.e., Sabouraud
dextrose agar (SDA), SDA with 1% Tween 80 and 1.5% yeast extract, and Casitone agar [20,36,47–49].
Although these media are likely to adequately support the growth of Malassezia, they were not
evaluated with regard to their fitness in producing clear inhibition zone edges. The medium
recommended in the CLSI reference assay (document M44-A2) is Mueller–Hinton (MH) agar
supplemented with 2% glucose (G) and methylene blue (M). This medium allows obtaining clear
inhibition zone edges and less intrazonal growth, enabling easy interpretation of the inhibition zone
diameters [29]. Findings of a recent study [55] support the validity of this medium also for susceptibility
testing of M. pachydermatis with agar diffusion procedures against two azole drugs (CTZ and MCZ),
provided that the yeast inoculum is prepared with a lipid source (Tween 40 and Tween 80). With this
medium, the inhibition zones were definite and clear, facilitating the measurement of zone size and
minimizing subjectivity. Moreover, the inhibition zones correlated with the MIC values obtained
in a broth dilution assay [55] (Figure 2).
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MH agar with glucose and methylene blue might be preferable to SDA, that was employed in past
studies of M. pachydermatis using the disk diffusion method, SDA has been reported, even though
in a different test format (agar dilution assay), to obfuscate the antifungal activity of some antifungal
agents, such as 5-fluorocytosine, CTZ, and MCZ [67,68].
With regards to the E-test method, the growth media employed were Yeast nitrogen agar [41],
SDA [19,53], RPMI 1640 agar with ox bile, glycerol, glycerol monostearate and Tween 20 [62],
Dixon agar [54], and SDA with Tween 80 [16] or Tween 40 [63]. No author reported particular
problems using these media (e.g., poor growth, difficulty in the interpretation of inhibition zones, etc.).
3.1.4. The Inoculum Preparation
This parameter has a recognized impact on in vitro determinations, and a detailed procedure
has been developed to allow the production of definite and reproducible inocula of Candida spp. and
Cryptococcus spp. [27].
For M. pachydermatis, most of the authors agree that, in order to counteract the slower growth
rate of this organism compared to that of the Candida species, the inoculum size should be increased
compared to that recommended in the CLSI documents (Table 1). This should provide a suitable
growth of the yeast, allowing for easy interpretation of MICs/inhibition zones after 2–3 days of
incubation. Instead, lower-concentration inocula have been employed on occasion (see Table S1).
However, the problem centres not so much on the final inoculum size to be employed, but rather its
standardization and reproducibility. There are two main reasons for this. The first is the tendency of
M. pachydermatis cells to form clumps, owing to its butyrous nature, which makes it difficult to produce
homogeneous cell suspensions, thus yielding inconsistent CFU results [70]. Second, in order to adjust
the cell suspensions to the desired concentration, the density of the suspension should be assessed
by a spectrophotometer. However, while parameters for this calculation are defined for Candida spp.
and Cryptococcus spp., with regard to M. pachydermatis it is still unclear how to relate with precision of
the absolute optical density (OD) value to the corresponding CFU. With regards to the first difficulty,
both physical and/or chemical methods have been reported to minimize clumping. Methods that
have been employed include the use of dispersing agents, such as Tween, which is principally used
as a lipid source but it is also a mild detergent, and vortexing with glass beads [34,62]; using Tween
alone [58]; and employing a glass homogenizer [50]. An ultrasonic homogenizer has been also
reported to efficiently disperse clumps of M. pachydermatis, without affecting the yeast viability [70].
Issues surrounding standardization remain to be clarified. Various OD values at different wavelengths
have been employed to calculate the final quantity of M. pachydermatis cells in suspension. For example,
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according to Murai et al. (2002) [50] a suspension matching a transmittance of 1.0 at 660 nm will
yield 2.5 × 106 cells/mL, while Rincon et al. (2006) [58] and Pietschmann et al. (2008) [56] suggested
respectively that an absorbance of 0.425 to 0.435 at 530 nm wavelength and of 0.42 to 0.43 at 530 nm
wavelength will yield a suspension containing 106 CFU/mL. No method has been further validated by
inter-laboratory comparisons to produce a consensus procedure.
Another technique has been proposed to adjust inocula, i.e., by performing quantitative viable
counts, that is by culturing progressive dilutions of the original suspension and counting the number
of CFU/mL thus obtained [43]. However, these viable counts, which relate the suspension density
to the number of yeast cells present in it, are necessarily retrospective. They allow the inoculum
concentration to be determined only after some days of incubation. Therefore, the inoculum can
only be adjusted for use in tests after a prolonged incubation of the original suspension which,
in the meantime, may have reduced viability.
Another issue that may be worth standardizing is the type of agar on which subcultures should
be performed to obtain colonies for susceptibility tests and the number of subcultures that should
be performed before testing. Repeated passages may enhance viability and subsequently lead to
optimal growth in test media, however this will also delay the results of the tests. In this regard,
we have already underlined the suggested use of subcultures on lipid-enriched media to allow for
the subsequent growth in lipid free broths [17], that are less likely to interfere with the activity of
the antifungals under testing.
In the CLSI disk diffusion assay, the recommended inoculum is equal to 0.5 McFarland
standard (1 × 106–5 × 106 CFU/mL) [27,29] (Table 1). For this type of assay, with regard to
M. pachydermatis, this inoculum was shown to not provide adequate confluent growth on agar
plates, and higher-concentration inoculum (1 × 107–5 × 107 CFU/mL)—prepared with a lipid
enrichment—was thus necessary [55]. Bernardo et al. (1998) [36] reported using an inoculum
corresponding to a 2 McFarland turbidity standard, without specifying the corresponding number
of colony forming units (CFU).
3.1.5. Temperature and Length of Incubation
With a temperature between 32 and 37 ◦C, no more than 2 or 3 days are generally
needed to obtain an adequate growth of M. pachydermatis in vitro. Thus, it should be possible
to read MICs/inhibition zones at 72 h or even 48 h. Indeed, most studies adopted these
times of reading [15–18,33–37,39–44,47,49–59,61–65]. However, extended incubation times, up to
7 days, were sometimes reported as necessary, especially in cases where the AD method
was employed [38,45,51,60]. While any length of incubation is potentially suitable, provided that it
allows an easy interpretation of MICs or inhibition zones and allows the production of reproducible
results, in order to facilitate the timely production of results to enhance clinical management,
shorter incubation times are preferable provided that the results are consistent and clinically relevant.
In this regard, a recent study suggests that a 48 h incubation may be now recommended since no
statistically significant differences were noted between 48 and 72 h MIC values [33].
3.1.6. The Method of End-Point Determination in Broth- and Agar-Dilution Assays
For broth susceptibility testing, the turbidity of the medium, by visual assessment,
is recommended as an indicator of fungal growth in the CLSI standard. As a modification,
spectrophotometric reading has been studied by several investigators, resulting in favorable agreement
rates with visual evaluation in general, and this method of assessment is employed in the EUCAST
tests [27,28]. With regards to M. pachydermatis, as discussed, its tendency to form clusters makes it
form a button-like deposit in the tubes and in the microdilution wells, rather than produce a diffuse
turbidity of the medium, as seen with Candida spp. (Figure 3).
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Figure 3. Microplate (U-bottom wells) for susceptibility testing of a M. pachydermatis isolate against
three antifungal drugs tested in duplicate, MCZ (rows 1 and 2); TBD (rows 3 and 4); CTZ (rows 5
and 6). Growth medium: Christensen Broth with Tween 40 and 80 as a lipid source. The last column on
the right comprises the drug-free growth controls. The last column on the left is the negative control
(no yeast inoculum; no drug) and the two bottom rows are also inoculum free. The rows of wells
contain doubling dilutions of the drugs from 16 to 0.03 µg/mL with the highest concentration to the left
of the plate. For this experiment, the MICs were 2, >16, and 4 µg/mL, respectively, for MCZ, TBD,
and CTZ. The plate was not agitated prior to reading. It can be seen how the yeast isolate formed
button-like deposits in the wells.
In this respect, Malassezia is similar to C. neoformans, which also tends to precipitate [27].
Accordingly, past experience on this latter organism has shown that agitation of the plates is useful
for interpreting end points [71]. Also for Candida species, agitation of the plates appears to
enhance visual reading and, for both Cryptococcus and Candida, agitation is deemed necessary
before spectrophotometric reading [71]. These findings may suggest that also for M. pachydermatis
the agitation of the plates prior to reading could make MICs easier to read and more reproducible.
However, this lacks experimental evidence, given that this part of the procedure is not detailed
in most studies. Our personal experience [34] might even suggest the contrary as we found the size
of the button-like deposits of the yeast made the end-point easily quantifiable, while agitation often
made this quantitative evaluation more difficult. Moreover, the relative sizes of the buttons correlated
well with the OD values obtained by the spectrophotometer. We also noted that in flat-bottomed
wells, more uniform suspensions were generated (Figure 1), while deposits of the yeast occurred when
U-shape wells were used (Figure 3). Although this technical detail appears to be regarded as of little
importance in the literature concerned with AFST of Malassezia, with very few studies specifying
the type of microplates used, it should be remembered that the form of the wells is an important
parameter, given that it is mentioned in the CLSI/EUCAST documents (Table 1) [27].
Two colorimetric methods have been proposed to evaluate MICs for M. pachydermatis as
an alternative to turbidimetric reading. The first is based on the detection of fungal metabolic activity
through an indicator of ox-red activity (Alamar blue). This method was employed to read MICs when
tests were performed in a turbid medium, that is the Leeming-Notman broth [43,59]. In the second
colorimetric assay, the urea incorporated in the test medium (modified Christensen’s urea broth)
was converted to ammonia by the urease activity of the yeast, resulting in an alkaline change in the pH
of the medium proportional to the number of surviving yeast, resulting in a visible colour change from
yellow/clear to pink using a phenol red pH indicator. The colour change was assessed visually or
by a more objective assessment made by a spectrophotometer [50,51,56,58]. Some commercial kits,
based on colorimetric (ox-red) reading are available for testing Candida spp. The levels of agreement
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of some of them with the reference methods may support the validity of this indirect approach that
is rapid and easy to employ [28]. However, as far as M. pachydermatis is concerned, it is logical to think
that, since various lipid media that allow an easy assessment of the yeast growth are available, a simpler
turbidimetric approach should be standardized, from which more complex indirect colorimetric assays
could be developed. Our experience supports this caution, since we employed the urease method and
noted that the colour change was often inconstant and sometimes absent (Figure 1). In fact, while urease
production is considered as an important trait of M. pachydermatis [66], its intensity can vary according
to the growth conditions and it can even disappear in strains that have been stored for long periods [38].
Moreover, we suspect that the measurement of colour change instead of the medium turbidity might
be too stringent, with consequent underestimation of the antifungal activity. As an example of this
effect, the results presented by Nakamura et al. (2000) [51] and Murai et al. (2002) [50] show ITZ MICs
several-fold higher than that found by most authors (Table 2).
A third approach for reading MICs in microtitre plates has been proposed. Prado et al. (2008) [57]
and Brito et al. (2009) [37] claimed that reading of MICs in microtitre plates was difficult due to
the sedimentation of Malassezia in the bottom of the wells and proposed overcoming the problem
by subculturing aliquots of broth, taken at the end of the incubation period, on potato dextrose agar.
Even though MICs obtained by this procedure were similar to those found in most studies, a finding
that may demonstrate the validity of this approach, we believe that this modification is cumbersome,
time consuming, and unnecessary. We think that MICs for M. pachydermatis can be read and interpreted
quite easily (see Figures 1 and 3) and that there are other ways to help visual interpretation, such as
the use of spectrophotometer reading, which is more suitable. In support of this, a difficult reading of
the yeast growth is rarely mentioned in the literature.
Regardless the way the yeast growth is evaluated (turbidimetric vs. colorimetric reading),
the MIC endpoint that is adopted is also of major importance [71]. For Candida/Cryptococcus,
CLSI defines the MIC as the lowest drug concentration at which there is substantial reduction of growth
(approximately 50%) compared to growth in the drug-free control. Application of this less-stringent
endpoint is recommended for azole drugs, due to their fungistatic nature. For Candida spp.,
this phenomenon can result in a partial inhibition of growth over an extended range of antifungal
concentrations, with the suspension failing to become optically clear (the so-called trailing end point).
Application of this endpoint has improved inter-laboratory agreement and also discriminates between
putatively susceptible and resistant isolates of Candida spp. [25]. With fungicidal agents such as AMB
and TER, growth ceases upon exposure to the drug; this results in clear-cut endpoints. Accordingly,
for such agents, the MIC is the lowest drug concentration that results in optically clear medium [72].
It is hard to know now which end point determination will produce the most reproducible and
representative MICs for M. pachydermatis. Concerning the azoles, some authors have referred to
an MIC definition as the level of 50% inhibition of growth compared with drug-free growth control
(which mirrors the MIC endpoint recommended for Candida and Cryptococcus), whilst others used
a 90%, 99%, or 100% inhibition level. Velegraki et al. (2004) [62] found that the trailing growth
phenomenon was only weakly displayed by Malassezia spp. and they therefore suggested a 90%
endpoint. However, their study was mainly focused on other Malassezia species and included only
one strain of M. pachydermatis. It is also unclear if different end points should be applied to different
antifungals, as for Candida testing. It appears that some authors have maintained the same MIC
endpoint for azoles and AMB [38] and for azoles and TER [50], while others have adapted it according
to the antifungal class [37,57,62].
3.1.7. The Quality Controls (QC)
The goals of a QC program are the following: (i) the precision (and repeatability) and
accuracy of the susceptibility test procedure; (ii) the performance of the reagents, testing conditions,
and instructions used in the test; and (iii) the performance of persons who conduct the tests and read
the results [25]. The goals are well realized by, although not limited to, the use of reference strains.
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By including reference strains that are known to provide defined MICs/inhibition diameters under
the test conditions employed, the user can monitor the performances of the laboratory procedure
over time. Moreover, it is useful to compare inter-laboratory results. CLSI standards include
recommendations for specified strains from the American Type Culture Collection (ATCC) to be used as
QC strains [25,26,29]. Due to the lack of a standard testing methodology, QC strains of M. pachydermatis
are not available yet. As reported above, some authors overcome this problem by using the Candida
and Cryptococcus QC strains [57,58]. In other cases, random repetitions of the tests were performed to
test the reproducibility of the results obtained, while some authors did not monitor their results by any
QC measure.
4. Conclusions and Perspectives
Analogous to the standardization of Candida/Cryptococcus susceptibility testing, it is likely
that the analysis and standardization of each of the test condition parameters might increase
the reproducibility of methods for susceptibility testing of M. pachydermatis. It is advisable to develop
a standard procedure that can be carried out through a multicenter approach, resulting in broad
consensus from the scientific community. Some of the testing options reported in the literature appear
suitable and worth adopting in a future reference standard dedicated to this yeast. A microtitre plate
broth format, with turbidity as a growth indicator and a medium as simple and definable as possible,
with any lipid supplementation which is often cited as the cause of drug interference [73] reduced to
the minimum that is necessary to support the yeast growth, is likely to represent the best starting point.
Avoiding the unnecessary use of lipid supplementation will also reduce the difficulty encountered
in interpreting endpoints due to the added turbidity afforded by the lipid enrichment. The two culture
media that may be now considered the most suitable for testing M. pachydermatis are Christensen’s broth
with Tween 40/80 and Sabouraud Broth with Tween 80, because they were shown to not antagonize
the drug activity and to support the adequate growth of the yeast [15,33,34,40,58]. Moreover, they have
a well-defined and reproducible formula.
Other test formats may be of interest as well, e.g., agar dilution procedures. For this type of assay,
Leeming–Notman agar may be recommended since it was shown not to antagonize the activity of
the drugs under testing [45]. The E-test® method also appears promising, as it allows MIC values to
be obtained, but via a more simplified agar diffusion procedure. However, a limitation is that the strips
are not commercially available for all antifungal agents used in dogs.
On the other hand, we think that the disk diffusion technique, although more practical and easy to
apply, should be employed only once a reproducible broth-based technique is available. In fact, this will
represent the basis of verifying the functioning of disk-diffusion and the correlation of inhibition zones
with MIC values. For the disk diffusion format, we would suggest the use of Mueller-Hinton Agar
with glucose and methylene blue, for the reasons discussed above.
For all formats, much work must still be done to standardize the inoculum preparation. The use
of dispersing agents, such as Tween, together with mechanical methods, will probably guarantee
the best result in dispersing Malassezia clumps, thus facilitating the production of homogenous
suspensions with reproducible CFU. Following this, parameters will have to been determined as far as
the spectrophotometer reading is concerned (i.e., the wavelength, the OD values, and the corresponding
number of CFU).
Regarding the MIC definition in the broth and agar dilution assays, further experiments
are necessary with a large number of isolates to clarify the “in vitro behaviour” of M. pachydermatis
in the presence of each of the antifungal drug classes that possess different mechanisms of action,
and the consequent optimal end point for each of them.
For any procedure, another key step will be the establishment of a QC regimen with specified
strains of M. pachydermatis selected as QC strains. For this selection, it should be taken in account
that the ideal reference strains for QC of the dilution methods have MICs that fall near the midrange
of the concentration for all of the antifungal agents tested. Moreover, before a strain is accepted as
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a reference, it should be tested for as long as is necessary to demonstrate that its antifungal susceptibility
pattern is genetically stable [25]. One candidate could be the already cited CBS strain 1879 which will
be sustainable and readily accessible as it is already stored in a culture collection. The use of reference
strains will also allow the comparison of results between different laboratories and published reports.
In conclusion, once a method has been shown to provide results with good inter- and
intra-laboratory agreement, the challenge will be to evaluate the correlation of in vitro data with
clinical outcomes. This will be mandatory in order to ascertain the clinical relevance of these
in vitro determinations.
Supplementary Materials: The following are available online at www.mdpi.com/2309-608X/3/3/37/s1,
Table S1: Detailed description of previous studies concerned with in vitro susceptibility testing of M. pachydermatis
(test format, test conditions, main results, etc.).
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